Cozad Asset Management Inc. Has $696,000 Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Cozad Asset Management Inc. decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,531 shares of the biopharmaceutical company’s stock after selling 504 shares during the quarter. Cozad Asset Management Inc.’s holdings in Gilead Sciences were worth $696,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Avior Wealth Management LLC raised its position in Gilead Sciences by 1.2% during the third quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock valued at $782,000 after purchasing an additional 108 shares in the last quarter. Southland Equity Partners LLC increased its stake in shares of Gilead Sciences by 3.6% in the 4th quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 110 shares during the last quarter. Berkshire Bank raised its holdings in shares of Gilead Sciences by 3.4% during the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock worth $314,000 after buying an additional 111 shares in the last quarter. CFO4Life Group LLC lifted its position in shares of Gilead Sciences by 2.7% during the 4th quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company’s stock worth $394,000 after buying an additional 112 shares during the last quarter. Finally, GHP Investment Advisors Inc. boosted its stake in Gilead Sciences by 1.1% in the fourth quarter. GHP Investment Advisors Inc. now owns 11,354 shares of the biopharmaceutical company’s stock valued at $1,049,000 after buying an additional 122 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at $12,626,253.06. This trade represents a 52.26 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders sold 302,785 shares of company stock valued at $30,503,250. 0.16% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

GILD has been the subject of a number of research reports. Cantor Fitzgerald reissued a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a research report on Thursday, February 13th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, February 12th. Piper Sandler raised their price objective on Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Finally, Daiwa America raised Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $104.52.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $112.26 on Tuesday. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96. The firm has a 50 day moving average of $102.24 and a 200-day moving average of $93.16. The company has a market cap of $139.80 billion, a price-to-earnings ratio of 303.41, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a $0.79 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.81%. The ex-dividend date is Friday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 854.05%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.